Building a global regenerative medicine leader.
Excellent MedTech is scaling its commercial, regulatory, and manufacturing footprint globally. We are looking for strategic investors who share our long-term vision for the regenerative medicine industry.
Why Excellent MedTech?
Three integrated platforms
ME-Fab® (commercialised), ME-Regen® (pre-clinical), Cell home® (pre-clinical) — three technology platforms integrated into a single patient-care continuum. Few medtech companies have this depth.
Standards-led moat
Co-author of 10 national guidelines, 2 expert consensuses, 2 group standards. 60+ IP rights. The standards are the moat.
Market-validated
5,000+ clinical cases, 500+ hospital partners, < 2% total complication rate, NMPA Class III approved. 3 months to reimbursement coding, 1 month for multi-province pricing.
USD 1.3B → USD 3.3B by 2032
3D-printed CMF market growing at 14.8% CAGR. Patient-matched segment growing at 20%+. We are positioned in the fastest-growing sub-segment.
Cross-disciplinary excellence
Founders and core team include National Science & Technology Progress Award winners, provincial-level technology invention award winners, and senior clinicians.
Clear exit pathways
HK IPO or strategic M&A. Target 2028 for restructuring; HK listing targeted by 2030. M&A by global medtech leaders also in play.
Where we are. Where we're going.
Indicative projections; actual results may vary. Full financial model available to qualified investors under NDA.
Use of proceeds.
Capacity expansion
Build 5,000 m² GMP-standard production halls. Resolve capacity bottleneck. Add EBM cells and automated post-processing.
National market expansion
Build academic promotion team. Cover core tertiary hospitals and distributor network in priority provinces.
R&D investment
CMF, spine, and orthopaedic product line expansion. Drive bio-active regenerative bone pilot trials.
Short, medium, and long term.
Short term (1–2 years)
- 2026 revenue: RMB 50M+
- 5,000 m² Phase II GMP facility operational
- ME-Regen® and Cell home® clinical trial launch
- CE-MDR achieved, FDA 510(k) cleared
Medium term (3–5 years)
- Domestic market leadership in skeletal & soft-tissue repair
- Two-engine growth: implants + regenerative products
- Global footprint in 25+ countries
- Net profit: RMB 200M → 400M trajectory
Long term (5+ years)
- Global medtech platform company
- Three-platform product portfolio fully commercialised
- Multiple late-stage pipeline products
- HK listing or strategic M&A exit
Pathway to liquidity.
HK IPO
Targeted by 2030. HKEX Chapter 18A (biotech) or main board. The Class III approval and CE-MDR achievement are key milestones for the listing prospectus.
Strategic M&A
Global medtech leaders have shown strong interest in the 3D-printed CMF space. M&A pathway remains an option at any stage.
Investor contact.
For Series A+ discussion, due diligence materials, and management meetings.